Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences NanoPharmaceuticals

Jagat Kanwar's Biography

Jagat Kanwar, Professor, Deakin University

Professor Jagat Kanwar is group leader and head of the Nanomedicine and Laboratory of Immunology and Molecular Biomedical Research has an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. Our nanomedicine laboratory of immunology and molecular biomedical research (NLIMBR) is discovering the novel and safe targeted nanomedicine based nano-nutraceuticals for cancers, autoimmune disorders and inflammatory diseases. We also vested the molecular diagnosis including role of a non-invasive exosomes in blood, inflammatory sites and cancer tissues. Our research focused on cancer and inflammatory autoimmune diseases aims to investigate the underlying mechanisms involved in apoptosis, autophagy and inflammation by targeting the production of cytokines, chemokines, oxygen radicals and matrix metalloproteinase. Our research also aims to investigate the nanotherapeutics encapsulating peptides, LNA modified aptamers/miRNAs/siRNA in vivo models. We have made significant progress in field of ocular drug delivery and microfluidic and Lab-on-a-Chip devices techniques for cancer cells as well as stem cell capture, disease specific biomarkers and exosomes. His publications more than 150 research papers and have added to the body of knowledge in the fields of nanobiotechnology, cancer gene therapy, cell biology and immunology. Kanwar's research work has generated a total of 12 patent/PCTs. He is the member of various scientific committees and societies.

Jagat Kanwar Image

Nanopharmaceuticals Approaches with Locked Nucleic Acid Aptamers in Cancer

Thursday, 10 September 2015 at 10:35

Add to Calendar ▼2015-09-10 10:35:002015-09-10 11:35:00Europe/LondonNanopharmaceuticals Approaches with Locked Nucleic Acid Aptamers in CancerNanoPharmaceuticals in

This Presentation will discuss regarding the role of P-glycoprotein, Survivin and CD133 positive cancer stem cells for enhancing Cancer resistance, promoting Cancer Survival and recurrence. Further, it will also highlight the delivery of Fe-bLF-ACSC NanoCarriers, oligo LNA siRNA, Nanoparticles loaded with SR9 and LNAsiRNA-5-FU to target and inhibit survivin which has a direct inhibitory effect on p-gp and CD133 CSCs.


Add to Calendar ▼2015-09-10 00:00:002015-09-11 00:00:00Europe/LondonNanoPharmaceuticalsNanoPharmaceuticals in